NVS
Stock Details
NVS is Novartis AG's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 80.12$. Average daily volumn in 3 months 2.35M. Market cap 194.04B
Stock symbol : NVS. Exchange : NYSE. Currency : USD Lastest price : 89.82$. Total volume : 1.47M. Market state PREPRE Click reload if you want to check the lastest price on market!!!
Novartis AG (NVS)
Last Price
89.82$Change
0.26Volume
1.47M
| Previous Close | 89.56 |
| Open | 89.72 |
| Day Range | 89.46-89.96 |
| Bid | 0.00 x 1.2k |
| Ask | 0.00 x 1k |
| Volume | 1.47M |
| Average Volume | 2.35M |
| Market Cap | 194.04B |
| Beta | 0.51 |
| 52 Week Range | 74.09-94.26 |
| Trailing P/E | 9.26 |
| Foward P/E | 14.01 |
| Dividend (Yield %) | 3.81% |
| Ex-Dividend Date | 2022-03-08 |
Financial Details
Organization
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form me... dicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Market Cap:
194.04BRevenue:
52.88BTotal Assets:
131.79BTotal Cash:
12.41B
News about "Novartis AG"
Novartis AG (NYSE:NVS) Is Down -0.13% Year To Date; Analysts Say It Will Rally
Source from : stocksregister - 2 days ago
Novartis AG (NYSE:NVS) price is hovering higher on Wednesday, November 30, jumping 0.50% above its previous close. A look at today’s price movement shows that the recent level at last check reads $87.See details»
Novartis AG's (VTX:NOVN) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Source from : Yahoo Finance - 6 days ago
Novartis (VTX:NOVN) has had a great run on the share market with its stock up by a significant 5.6% over the last month. Given that stock prices are usually aligned with a company's financial ...See details»
Novartis (NVS) Set to Advance Malaria Drug Into Phase III
Source from : YAHOO!Finance - 8 days ago
Novartis (NVS) plans to advance ganaplacide/lumefantrine into a phase III study for the treatment of patients with acute uncomplicated malaria due to Plasmodium falciparum.See details»
With 53% ownership, Novartis AG (VTX:NOVN) boasts of strong institutional backing
Source from : Yahoo - 25 days ago
If you want to know who really controls Novartis AG (VTX:NOVN), then you'll have to look at the makeup of its share registry. With 53% stake, institutions possess the maximum shares in the company.See details»
Novartis Considers Sale Of Ophthalmology, Respiratory Units : Report
Source from : Nasdaq - 16 days ago
Novartis said in August that it planned to separate Sandoz, its generics and biosimilars division, into a new publicly traded standalone company through a 100 percent spin-off. Bloomberg reported ...See details»
Novartis Weighs Ophthalmology, Respiratory Unit Sales
Source from : Bloomberg L.P. - 16 days ago
Novartis AG is weighing sales of non-core assets as it seeks to raise money to invest in cutting-edge medicines, people familiar with the matter said. The Swiss pharmaceutical giant is in the ...See details»
Novartis weighs sale of ophthalmology, respiratory units - Bloomberg
Source from : Reuters - 16 days ago
REUTERS/Brian Snyder/File Photo Nov 16 (Reuters) - Swiss drugmaker Novartis AG (NOVN.S) is considering selling its ophthalmology and respiratory units, a Bloomberg report said on Wednesday ...See details»
Novartis AG
Source from : Wall Street Journal - 7 days ago
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...See details»
Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH
Source from : Business Insider - 10 days ago
and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of ...See details»
Novartis claims two firms are infringing its patent for multiple sclerosis drug
Source from : The Irish Times - 10 days ago
Switzerland-based Novartis AG, and its Irish affiliate, Novartis Ireland Ltd, claim Accord and Mylan are breaching their patent on Gilenya.The medicine is used in the treatment of relapsing ...See details»
Novartis Pharma AG: New long-term Leqvio (inclisiran) data from Novartis show sustained efficacy and safety over four years
Source from : Finanznachrichten - 24 days ago
and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of ...See details»
Novartis adds 50 million euros to European antibiotics investment budget
Source from : Yahoo News - 25 days ago
(Reuters) -Sandoz, the generic drugs business that will be spun off its parent Novartis, will boost investment in its European antibiotics production network by 50 million euros ($50 million) on ...See details»
Novartis weighs sale of ophthalmology, respiratory units - Bloomberg
Source from : Yahoo News - 16 days ago
(Reuters) -Swiss drugmaker Novartis AG is considering selling its ophthalmology and respiratory units, a Bloomberg report said on Wednesday, citing people familiar with the matter. The company is ...See details»
Novartis Considers Sale Of Ophthalmology, Respiratory Units : Report
Source from : Business Insider - 16 days ago
(RTTNews) - Novartis AG (NVS) is considering sales of non-core assets. It is in the early stages of considering options for its ophthalmology and respiratory units. Some private equity firms are ...See details»